Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients
Launched by UNIVERSITY MEDICAL CENTER GOETTINGEN · Jun 29, 2025
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • genetically diagnosed Retintis pigmentosa
- • minimum age of 18 years (legal adult age in Germany)
- • patient consent for study participation
- Exclusion Criteria:
- • lack of capacity to consent in participation of study (unconsciousness, mental capacity, mental illness)
- • reduced cooperation during imaging or examination
- • age under 18 years
- • presence of additional retinal diseases
- • insufficient imaging quality due to hazy media (cornea, lense)
About University Medical Center Goettingen
The University Medical Center Göttingen (UMG) is a leading academic institution in Germany, renowned for its commitment to advancing medical research and education. As a sponsor of clinical trials, UMG leverages its extensive expertise and state-of-the-art facilities to facilitate innovative research that aims to improve patient care and treatment outcomes. With a focus on interdisciplinary collaboration, UMG fosters partnerships across various medical fields, ensuring a comprehensive approach to clinical investigation. Its dedication to ethical standards and patient safety underscores its role in translating scientific discoveries into effective therapeutic solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Göttingen, , Germany
Patients applied
Trial Officials
Emilie Macé, Professor
Principal Investigator
Else Kroener Fresenius Center for Optogenetic Therapies, University Medical Center Goettingen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported